Monopar Therapeutics (MNPR) EBITDA (2017 - 2025)
Quarterly results put EBITDA at -$3.5 million for Q3 2025, down 164.71% from a year ago — trailing twelve months through Sep 2025 was -$9.8 million (down 48.22% YoY), and the annual figure for FY2024 was -$15.6 million, down 419.13%.
Monopar Therapeutics has reported EBITDA over the past 9 years, most recently at -$3.5 million for Q3 2025.
- EBITDA reached -$3.5 million in Q3 2025 per MNPR's latest filing, down from -$2.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$57.0 in Q2 2021 and bottomed at -$3.5 million in Q3 2025.
- Median EBITDA over the past 5 years was -$2.4 million (2025), compared with a mean of -$2.0 million.
- The largest annual shift saw EBITDA skyrocketed 100.0% in 2021 before it crashed 4809936.84% in 2022.
- Over 5 years, EBITDA stood at -$2.7 million in 2021, then decreased by 9.4% to -$2.9 million in 2022, then soared by 33.22% to -$2.0 million in 2023, then skyrocketed by 32.37% to -$1.3 million in 2024, then crashed by 164.71% to -$3.5 million in 2025.
- Business Quant data shows EBITDA for MNPR at -$3.5 million in Q3 2025, -$2.4 million in Q2 2025, and -$2.6 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 661.60 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.82 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -2.35 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Sep 30, 2024 | -1.32 Mn |
| Jun 30, 2024 | -1.71 Mn |
| Mar 31, 2024 | -1.62 Mn |
| Sep 30, 2023 | -1.96 Mn |
| Jun 30, 2023 | -2.22 Mn |
| Mar 31, 2023 | -2.41 Mn |
| Dec 31, 2022 | -2.93 Mn |
| Sep 30, 2022 | -2.37 Mn |
| Jun 30, 2022 | -2.74 Mn |
| Mar 31, 2022 | -584.00 |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -57.00 |
| Mar 31, 2021 | -1.88 Mn |
| Dec 31, 2020 | -2.13 Mn |
| Sep 30, 2020 | -1.64 Mn |
| Jun 30, 2020 | -1.44 Mn |
| Mar 31, 2020 | -1.09 Mn |
| Dec 31, 2019 | -1.21 Mn |
| Sep 30, 2019 | -744,819.00 |
| Jun 30, 2019 | -904,633.00 |
| Mar 31, 2019 | -1.38 Mn |
| Dec 31, 2018 | -890,472.00 |
| Sep 30, 2018 | -640,990.00 |
| Jun 30, 2018 | -640,990.00 |
| Mar 31, 2018 | -876,347.00 |
| Dec 31, 2017 | -713,583.00 |
| Sep 30, 2017 | -14.88 Mn |
| Jun 30, 2017 | -591,438.00 |
| Mar 31, 2017 | -373,839.00 |